Clinical Trial Update: Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is recruiting to evaluate low-dose tamoxifen with or without omega-3 fatty acids for breast cancer risk reduction in women with atypica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Atypical Hyperplasia
• Breast Cancer
• Breast Ductal Carcinoma in Situ
• Breast Lobular Carcinoma in Situ

Drugs mentioned

• Nolvadex (tamoxifen)
• Omega-3 fatty acids (omega-3 fatty acids)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Atypical Hyperplasia, Breast Carcinoma | Phase 2 | Status: RECRUITING